Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q46937457

about

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study Thymostimulin in advanced hepatocellular carcinoma: a phase II trial Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine.Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274 Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma Sorafenib in advanced melanoma: a critical role for pharmacokinetics?Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study Sorafenib suppresses the cell cycle and induces the apoptosis of hepatocellular carcinoma cell lines in serum-free media.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.Sorafenib combined with cryoablation to treat unresectable hepatocellular carcinoma Sorafenib for treatment of hepatocellular carcinoma: a systematic review.The androgen receptor as an emerging target in hepatocellular carcinoma Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.Newer treatments for advanced hepatocellular carcinoma.Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma.Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.Sorafenib for the treatment of unresectable hepatocellular carcinoma.

P2860

Q28392783-BAACC464-6A76-4738-9E7F-DEABB105BC05 Q28394414-A07FDEA0-992F-4AAD-A031-EBA86FEDE83D Q30460933-D1169C7C-2099-4FCF-BA6E-9473073649E1 Q33325625-B6BE9A7D-F40F-4027-95AE-C9B669A17AEF Q33404027-00A9CE21-92DB-4A21-84B3-ACCC9F471429 Q33404952-2E866931-F025-4AF3-A279-1FF679132CB7 Q33443438-3C3B1F70-F579-45C6-B97E-58CAB1C5FE5C Q33599232-7516EBF4-E7F6-41C4-8C37-05FE16B09429 Q33742856-1C94D324-DD6D-4725-A2E5-BF25068D31C3 Q33948042-1355F2F4-8B1D-421B-9988-43B00ED15F9F Q34001687-4C729A5D-2192-4A08-86B9-21654D7EC789 Q34200743-70F98D14-6C5B-4D11-B231-BAA80E8BDAF5 Q34265415-51B4058A-C5D8-43A0-9160-679025D325E1 Q35030418-D3BD3673-F975-46FA-92B9-5F1992D1962B Q35051975-6A64D6E6-5F78-4A97-96AA-53919E0CCD00 Q35963024-CFA5B5C2-CA1C-414C-97FC-4D943B9955CF Q36117220-CAD566D3-0CC2-47B1-90A9-5B7F9A50BAA3 Q36224737-7C506FF9-B794-4D96-B054-C9C767FD21AA Q36230740-611BE7D5-721B-4DBB-95A6-8E9EDE462F7A Q36244147-AB75E1E8-6C5D-4169-9DBE-7C8A4D39ED59 Q36270115-83600491-D91D-4F11-8D6E-894BD7C8692A Q36285672-1A04C346-5A13-45D7-8A5E-D3A98D5451F5 Q36644408-C3B4F379-CA95-4378-8F32-FF7EA56C74E6 Q36654704-0913FB61-8B04-4514-A31D-338356835ABB Q36680204-8314C19C-C911-4E65-BE61-6F380065CB9C Q37031766-6C4A7D70-CE34-440D-9322-8BE0D01388AB Q37283736-2D84240F-7720-4948-8C7B-47033163E887 Q37284654-97DB6BAD-9859-4966-B91F-C0C5604B219A Q37398733-B22C6F7C-B167-4CC4-AC41-71E94FAF3347 Q37441574-12407178-6C17-4DB2-8DB7-BBA18D4C7988 Q37642185-60814067-0AF8-4FCD-AEBD-AA268DF61495 Q37665692-E77A734C-DE24-4159-8AF3-AC567F472A07 Q37688711-D3AA1596-D1A6-46F3-9C98-36DDB07A4952 Q37701242-6E3A9BB5-DEA9-4165-A0BB-97E158968CFA Q37768896-323629D3-7BAE-4CBB-9272-60B38D9E636A Q37771252-978FD8B0-1FF6-4D71-B1E5-27C0EB0C7730 Q38155506-2FBEA982-ECBB-4942-B650-522C347C4ED9 Q38160838-8D4C9669-EACB-4D5B-8E81-0F01452ECD10 Q38173739-C5C85B68-3CD9-4486-8544-B4F2B6933231 Q39952324-F380191D-F9FD-47D2-B510-D3077BE3EA07

P2860

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

http://www.wikidata.org/entity/Q46937457

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@en

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@nl

type

label

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@en

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@nl

prefLabel

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@en

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@nl

P1433

Q46937457-6DBE79A4-B9A3-4D7E-B893-3CB9CAE01D4E

P1476

Q46937457-DD5D2180-34D2-460C-8D73-DD080C167F47

P2093

Q46937457-50271FAA-1A6E-4290-8B57-3EF49BF91BD1

Q46937457-7074C3F5-9048-4147-8DA7-5F132981C126

Q46937457-82499BAE-28AE-403C-AD69-04F6D37643F6

Q46937457-A2AFAA67-60D3-4A7D-B2FB-B2012A918F03

Q46937457-CF21EFCC-4AA3-40C9-ABFA-15EA2BBB46EE

Q46937457-DF2EAB3B-6B66-4A95-807D-141F06D50A99

P2860

Q46937457-0B4871AA-8DAE-4D25-974A-428BA1C1DACA

Q46937457-107CBC36-E0B8-4285-A45B-B5E27E4A692A

Q46937457-196FD6D5-83CB-421D-8D45-FE23B6696983

Q46937457-2225A973-446A-4266-AFED-C375843945F7

Q46937457-58B36AE4-2422-4D0B-BF4A-E3043E872B04

Q46937457-63103056-1006-4EB2-A0C0-D156AAA2B99C

Q46937457-7432E386-7868-4081-9BB7-547E48E058FB

Q46937457-851C42AA-174D-40A1-9395-7F8C1803C04A

Q46937457-9A297109-B65B-4B34-9CD8-01518B8E4218

Q46937457-9E2429B9-5B68-4F2D-930C-20D956D49AB4

P304

Q46937457-CA9B2571-7749-44CD-BA39-2F73930F7240

P31

Q46937457-E5DE246B-3527-402E-9016-1738543EF3BB

P356

Q46937457-1E667A1B-209D-4ABA-B622-AFAD30E08DD7

P433

Q46937457-2E36EC4A-EAE3-44EB-AAFD-B3F4FBB7F94D

P478

Q46937457-F981325B-0ABC-4F48-B2B8-4835211FDBCC

P577

Q46937457-A8303EE3-843D-45B8-AD7E-72ADA0A81A6A

P5875

Q46937457-AE4ED96A-87DE-4B74-937D-A41A3F7A2D3D

P698

Q46937457-104B2C3C-8794-4EF1-A1C5-B5DC80608D75

P921

Q46937457-ADF0E8BC-47F7-40F1-8C19-58AC15304BE3

P356

J.1349-7006.2007.00648.X

P1433

P1476

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.

@en

P2093

Eiichiro Suzuki

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ishii

http://www.w3.org/2001/XMLSchema#string

Junji Furuse

http://www.w3.org/2001/XMLSchema#string

Keiko Nakajima

http://www.w3.org/2001/XMLSchema#string

Kohei Nakachi

http://www.w3.org/2001/XMLSchema#string

Satoshi Shimizu

http://www.w3.org/2001/XMLSchema#string

P2860

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

BAY 43-9006: early clinical data in patients with advanced solid malignancies.

BAY 43-9006: preclinical data.

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.

P304

159-165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.2007.00648.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2007-10-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5891445

http://www.w3.org/2001/XMLSchema#string

P698

17953709

http://www.w3.org/2001/XMLSchema#string

P921